Skip to content

Study · Non-randomized trial · n = 28 · 1987

5 results

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.

Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E

The Journal of clinical endocrinology and metabolism1 Mar 1987Cited by 66 (Europe PMC)

PMID2880861 (opens in a new tab)DOI10.1210/jcem-64-3-447 (opens in a new tab)PepBankPUB-02880861
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly, octreotide produced a faster, greater and more prolonged plasma GH reduction than bromocriptine after a single dose.

    In plain wordsIn acromegaly, one octreotide dose lowered growth hormone faster, more and for longer than bromocriptine.

    Peptide
    Octreotide
    Outcome
    DecreaseAcute GH reduction
    Study

    n = 28

    Comparator
    Bromocriptine 2.5 mg orally
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    50 micrograms once · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A single dose of 50 micrograms SMS administered to 28 patients induced a more rapid, greater, and more prolonged reduction in plasma GH levels than did 2.5 mg Brc.
    2 context sentences
    Summary · context
    We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients.
    Summary · context
    The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc).
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly, chronic octreotide reduced mean plasma GH significantly more than bromocriptine during 60-330 days of treatment (mean 208 +/- 23 days).

    In plain wordsIn acromegaly, chronic octreotide lowered average growth hormone more than bromocriptine.

    Peptide
    Octreotide
    Outcome
    DecreaseChronic mean plasma GH
    Study

    n = 16

    Comparator
    Bromocriptine 20 mg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100-300 micrograms/day · subcutaneous · 60-330 daysAs given in this study (human).

    Source sentences

    Summary
    Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc.
    2 context sentences
    Summary · context
    We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients.
    Summary · context
    The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc).
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly, chronic octreotide reduced somatomedin-C significantly more than bromocriptine during 60-330 days of treatment (mean 208 +/- 23 days).

    In plain wordsIn acromegaly, chronic octreotide lowered somatomedin-C more than bromocriptine.

    Peptide
    Octreotide
    Outcome
    DecreaseChronic somatomedin-C
    Study

    n = 16

    Comparator
    Bromocriptine 20 mg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100-300 micrograms/day · subcutaneous · 60-330 daysAs given in this study (human).

    Source sentences

    Summary
    Chronic treatment [60-330 days; mean 208 +/- 23 (+/- SEM)] with SMS (100-300 micrograms/day) induced in 16 patients a significantly greater decrease in mean plasma GH and somatomedin-C levels than did 20 mg Brc.
    2 context sentences
    Summary · context
    We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients.
    Summary · context
    The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc).
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly, tumor size decreased during octreotide treatment in 3 of 10 patients assessed by CT before and during treatment.

    In plain wordsIn acromegaly, tumors became smaller during octreotide treatment in 3 of 10 patients compared with pretreatment scans.

    Peptide
    Octreotide
    Outcome
    DecreaseTumor size reduction
    Study

    n = 10

    Comparator
    Pretreatment CT
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Patients with reduced tumor size
    3 patients
    of 10 patients examined by CT before and during SMS treatment

    Source sentences

    Summary
    Reduction in tumor size occurred in 3 of the 10 patients examined by computed tomography before and during SMS treatment.
    2 context sentences
    Summary · context
    We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients.
    Summary · context
    The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc).
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly patients whose GH and somatomedin-C decreased with octreotide, clinical and metabolic parameters improved even without hormone normalization.

    In plain wordsIn acromegaly patients whose hormone levels fell with octreotide, clinical and metabolic measures improved compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    Direction not reportedClinical and metabolic parameters in hormonal responders
    Study

    n: not reported in source

    Comparator
    Pretreatment
    Outcome group
    Clinical and metabolic parameters · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS.
    2 context sentences
    Summary · context
    We studied the effects of acute and chronic sc administration of SMS 201-995 (SMS), a long-acting somatostatin analog, in acromegalic patients.
    Summary · context
    The results were compared with those obtained in the same patients treated with oral bromocriptine (Brc).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.